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AbstrACt
Over the last two decades, awareness of the negative 
repercussions of flaws in the planning, conduct and 
reporting of preclinical research involving experimental 
animals has been growing. Several initiatives have set 
out to increase transparency and internal validity of 
preclinical studies, mostly publishing expert consensus 
and experience. While many of the points raised in these 
various guidelines are identical or similar, they differ in 
detail and rigour. Most of them focus on reporting, only 
few of them cover the planning and conduct of studies. 
The aim of this systematic review is to identify existing 
experimental design, conduct, analysis and reporting 
guidelines relating to preclinical animal research. A 
systematic search in PubMed, Embase and Web of Science 
retrieved 13 863 unique results. After screening these 
on title and abstract, 613 papers entered the full- text 
assessment stage, from which 60 papers were retained. 
From these, we extracted unique 58 recommendations on 
the planning, conduct and reporting of preclinical animal 
studies. Sample size calculations, adequate statistical 
methods, concealed and randomised allocation of animals 
to treatment, blinded outcome assessment and recording 
of animal flow through the experiment were recommended 
in more than half of the publications. While we consider 
these recommendations to be valuable, there is a striking 
lack of experimental evidence on their importance and 
relative effect on experiments and effect sizes.
InTroducTIon
In recent years, there has been growing 
awareness of the negative repercussions of 
shortcomings in the planning, conduct and 
reporting of preclinical animal research.1 2 
Several initiatives involving academic groups, 
publishers and others have set out to increase 
the internal validity and reliability of primary 
research studies and the resulting publica-
tions. Additionally, several experts or groups 
of experts across the biomedical spectrum 
have published experience and opinion- based 
guidelines and guidance. While many of the 
points raised are broadly similar between these 
various guidelines (probably in part reflecting 
the observation that many experts in the 
field are part of more than one initiative), 
they differ in detail, rigour and, in particular, 
whether they are broadly generalisable or 
specific to a single field. While all these guide-
lines cover the reporting of experiments, only 
a few specifically address rigorous planning 
and conduct of studies,3 4 which might increase 
validity from the earliest possible point.5 
Consequently, it is difficult for researchers to 
choose which guidelines to follow, especially at 
the stage of planning future studies.
We aimed to identify all existing guidelines 
and reporting standards relating to experi-
mental design, conduct and analysis of preclin-
ical animal research. We also sought to identify 
literature describing (either through primary 
research or systematic review) the preva-
lence and impact of perceived risks of bias 
pertaining to the design, conduct and anal-
ysis and reporting of preclinical biomedical 
research. While we focus on internal validity as 
influenced by experimental design, conduct 
and analysis we recognise that factors such as 
animal housing and welfare are highly relevant 
to the reproducibility and generalisability of 
experimental findings; however, these factors 
are not considered in this systematic review.
Methods
The protocol for this systematic review has 
been published in ref 6. The following s
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amendments to the systematic review protocol were 
made: in addition to the systematic literature search, to 
capture standards set by funders or organisations that are 
not (or not yet) published, it was planned to conduct a 
Google search for guidelines published on the websites 
of major funders and professional organisations using 
the systematic search string below.6 This search, however, 
yielded either no returns, or, in the case of the National 
Institute of Health, identified over 193 000 results, which 
was an unfeasibly large number to screen. Therefore, 
for practical reasons this part of the search was excluded 
from the initial search strategy. Reassessing the goals of 
this review, we decided to focus on internal validity, in the 
protocol we used the term ‘internal validity and repro-
ducibility’. In the protocol, we mention that the aim of 
this systematic review is an effort to harmonise guidelines 
and create a unified framework. This is still under way 
and will be published separately.
search strategy
We systematically searched PubMed, Embase via Ovid 
and Web of Science to identify the guidelines published 
in English language in peer- reviewed journals before 
10 January 2018 (the day the search was conducted), 
using appropriate terms for each database optimised 
from the following search string (as can be found in the 
protocol6):
(guideline OR recommendation OR recommen-
dations) AND (‘preclinical model’ OR ‘preclinical 
models’ OR ‘disease model’ OR ‘disease models’ OR 
‘animal model’ OR ‘animal models’ OR ‘experimental 
model’ OR ‘experimental models’ OR ‘preclinical 
study’ OR ‘preclinical studies’ OR ‘animal study’ OR 
‘animal studies’ OR ‘experimental study’ OR ‘experi-
mental studies’).6
Furthermore, as many of the researchers participating 
in the European Quality in Preclinical Data project 
(http:// eqipd. org/) are experts in the field of experi-
mental standardisation, they were contacted personally 
to identify additional relevant publications.
Inclusion and exclusion criteria
We included all articles or systematic reviews in English 
which described or reviewed guidelines making recom-
mendations intended to improve the validity or reliability 
(or both) of preclinical animal studies through opti-
mising their design, conduct and analysis. Articles that 
focused on toxicity studies or veterinary drug testing were 
not included. Although reporting standards were not the 
key primary objective of this systematic review these were 
also included, as they might contain useful relevant infor-
mation.
screening and data management
We combined the search results from all sources and 
identified duplicate search returns and the publication 
of identical guidelines by the same author group in 
several based on the PubMed ID, DOI, and the title, 
journal and author list. Unique references were then 
screened in two phases: (1) screening for eligibility 
based on title and abstract, followed by (2) screening 
for definitive inclusion based on full text. Screening was 
performed using the Systematic Review Facility (SyRF) 
platform (http:// syrf. org. uk). Ten reviewers contrib-
uted to the screening phase; each citation was presented 
to two independent reviewers with a real- time computer- 
generated random selection of the next citation to be 
reviewed. Citations remained available for screening 
until two reviewers agreed that it should be included 
or excluded. If the first two reviewers had disagreed the 
citation was offered to a third, but reviewers were not 
aware of previous screening decisions. A citation could 
not be offered to the same reviewer twice. Reviewers 
were not blinded to the authors of the presented 
record. In the first stage, two authors screened the title 
and abstract of the retrieved records for eligibility based 
on predefined inclusion criteria (see above). The title/
abstract screening stage aimed to maximise sensitivity 
rather than specificity—any paper considered to be of 
any possible interest was included.
Articles included after the title- abstract screening 
were retrieved as full texts. Articles for which no full- 
text version could be obtained were excluded from 
the review. Full texts were then screened for definite 
inclusion and data extraction. At both screening stages, 
disagreements between reviewers were resolved by addi-
tional screening of the reference by a third adjudicating 
reviewer, who was unaware of the individual judgements 
of the first two reviewers. All data were stored on the 
SyRF platform.
extraction, aggregation and diligence classification
From the publications identified, we extracted recom-
mendations on the planning, conduct and reporting of 
preclinical animal studies as follows:
Elements of the included guidelines were identified 
using an extraction form (box 1) inspired by the results 
from Henderson et al.5 Across guidelines, the elements 
were ranked based on the number of guidelines in which 
that element appeared. Extraction was not done in dupli-
cate, but only once. As the extracted results in this case 
are not quantitative, but qualitative, meta- analysis and 
risk of bias assessment are not appropriate for this review. 
Still, we applied a diligence classification of the guide-
lines based on the following system, improving level of 
evidence from 1 to 3 and support from A to B:
1. Recommendations of individuals or small groups of 
individuals based on individual experience only.
A. Published stand- alone.
B. Endorsed or initiated by at least one publisher or sci-
entific society as stated in the publication.
2. Recommendations by groups of individuals, through 
a method which included a Delphi process or other 
means of structured decision- making.
A. Published stand- alone.
 3Vollert J, et al. BMJ Open Science 2020;4:e100046. doi:10.1136/bmjos-2019-100046
Open access
box 1 extraction form
1. Matching or balancing treatment allocation of animals.
2. Matching or balancing sex of animals across groups.
3. Standardised handling of animals.
4. Randomised allocation of animals to treatment.
5. Randomisation for analysis.
6. Randomised distribution of animals in the animal facilities.
7. Monitoring emergence of confounding characteristics in 
animals.
8. Specification of unit of analysis.
9. Addressing confounds associated with anaesthesia or 
analgesia.
10. Selection of appropriate control groups.
11. Concealed allocation of treatment.
12. Study of dose–response relationships.
13. Use of multiple time points measuring outcomes.
14. Consistency of outcome measurement.
15. Blinding of outcome assessment.
16. Establishment of primary and secondary end points.
17. Precision of effect size.
18. Management of conflicts of interest.
19. Choice of statistical methods for inferential analysis.
20. Recording of the flow of animals through the experiment.
21. A priori statements of hypothesis.
22. Choice of sample size.
23. Addressing confounds associated with treatment.
24. Characterisation of animal properties at baseline.
25. Optimisation of complex treatment parameters.
26. Faithful delivery of intended treatment.
27. Degree of characterisation and validity of outcome.
28. Treatment response along mechanistic pathway.
29. Assessment of multiple manifestations of disease phenotype.
30. Assessment of outcome at late/relevant time points.
31. Addressing treatment interactions with clinically relevant 
comorbidities.
32. Use of validated assay for molecular pathways assessment.
33. Definition of outcome measurement criteria.
34. Comparability of control group characteristics to those of previous 
studies.
35. Reporting on breeding scheme.
36. Reporting on genetic background.
37. Replication in different models of the same disease.
38. Replication in different species or strains.
39. Replication at different ages.
40. Replication at different levels of disease severity.
41. Replication using variations in treatment.
42. Independent replication.
43. Addressing confounds associated with experimental setting.
44. Addressing confounds associated with setting.
45. Preregistration of study protocol and analysis procedures.
46. Pharmacokinetics to support treatment decisions.
47. Definition of treatment.
48. Interstudy standardisation of end point choice.
49. Define programmatic purpose of research.
50. Interstudy standardisation of experimental design.
51. Research within multicentre consortia.
52. Critical appraisal of literature or systematic review during design 
phase.
53. (Multiple) free text.
Figure 1 Search flow chart. ARRIVE, Animal Research: 
Reporting of In Vivo Experiments.
B. Endorsed or initiated by at least one publisher or sci-
entific society as stated in the publication.
3. Recommendations based on a systematic review.
A. Published stand- alone.
B. Endorsed or initiated by at least one publisher or sci-
entific society as stated in the publication.
resulTs
search and study selection
A flow chart of the search results and screening process is 
found in figure 1. Our systematic search returned 13 863 
results, with 3573 papers from PubMed, 5924 from Web 
of Science and 5982 from Embase. After first screening 
on title and abstract, 828 records were eligible for the full- 
text screening stage. After removing duplications (69), 
non- English resources (48), conference abstracts (25), 
book chapters (14) and announcements (4), 676 records 
remained. Of these, 62 publications were retained after 
full- text screening. We later identified two further dupli-
cate publications of the same guidelines in different jour-
nals, giving a final list of 60 publications.5 7–65
The project members did not identify any additional 
papers that had not been identified by the systematic 
search.
diligence classification
More than half of the included publications 
(32) were narrative reviews that fell under the 
1A category of our rating system (recommenda-
tions of individuals or small groups of individuals 
based on individual experience only, published 
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Table 1 Extraction results
Recommendation
Absolute
frequency
Relative
frequency 
(%)
Adequate choice of sample size 41 68
Blinding of outcome assessment 41 68
Choice of statistical methods for 
inferential analysis
38 63
Randomised allocation of animals to 
treatment
38 63
Concealed allocation of treatment 31 52
Recording of the flow of animals 
through the experiment
31 52
A priori statements of hypothesis 30 50
Selection of appropriate control 
groups
29 48
Characterisation of animal properties 
at baseline
28 47
Addressing confounds associated 
with setting
23 38
Definition of outcome measurement 
criteria
23 38
Reporting on genetic background 23 38
Matching or balancing sex of animals 
across groups
20 33
Degree of characterisation and 
validity of outcome
19 32
Consistency of outcome 
measurement
18 30
Monitoring emergence of confounding 
characteristics in animals
18 30
Precision of effect size 18 30
Study of dose–response relationships 18 30
Addressing confounds associated 
with experimental setting
17 28
Establishment of primary and 
secondary end points
17 28
Reporting on breeding scheme 16 27
Assessment of outcome at late/
relevant time points
15 25
Independent replication 15 25
Matching or balancing treatment 
allocation of animals
15 25
Specification of unit of analysis 15 25
Randomisation for analysis 14 23
Replication in different species or 
strains
14 23
Standardised handling of animals 14 23
Addressing confounds associated 
with anaesthesia or analgesia
13 22
Replication in different models of the 
same disease
13 22
Addressing confounds associated 
with treatment
12 20
Continued
stand- alone).7 9 10 14 15 18 20 25 27 29 30 33 35 36 39 41–43 45 47–55 57 60 61 65 
An additional 22 publications were consensus papers 
or proceedings of consensus meetings for journals or 
scientific or governmental organisations (category 
1B).3 4 8 12 13 17 19 24 26 28 32 34 37 38 44 46 56 59 62–64 66 None of 
these reported the use of a Delphi process or systematic 
review of existing guidelines. The remaining six publi-
cations were systematic reviews of the literature (cate-
gory 3A).5 11 21 31 40 58
extracting components of published guidance
From the 60 publications finally included, we extracted 58 
unique recommendations on the planning, conduct and 
reporting of preclinical animal studies. The absolute and 
relative frequency for each of the extracted recommen-
dations is provided in table 1. Sample size calculations, 
adequate statistical methods, concealed and randomised 
allocation of animals to treatment, blinded outcome assess-
ment and recording of animal flow through the experiment 
were recommended in more than half of the publications. 
Only a few publications (≤5) mentioned preregistration 
of experimental protocols, research conducted in large 
consortia, replication at different levels of disease or by vari-
ation in treatment and optimisation of complex treatment 
parameters. The extraction form allowed the reviewers in 
free- text fields to identify and extract additional recommen-
dations not covered in the prespecified list, but this facility 
was rarely used, with only ‘publication of negative results’ 
and ‘clear specification of exclusion criteria’ extracted in 
this way by more than one reviewer. The full results table of 
this stage is published as csv file on figshare under the DOI 
10.6084/m9.figshare.9815753.
dIsCussIon
Based on our systematic literature search and screening 
using predefined inclusion and exclusion criteria, we 
identified 60 published guidelines for the planning, 
conduct or reporting of preclinical animal research. 
From these publications, we extracted a comprehensive 
list of 58 experimental rigour recommendations that the 
authors had proposed as being important to increase the 
internal validity of animal experiments. Most recommen-
dations were repeated in a relevant proportion of the 
publications (sample size calculations, adequate statis-
tical methods, concealed and randomised allocation of 
animals to treatment, blinded outcome assessment and 
recording of animal flow through the experiment in 
more than half of the cases), showing that there is at least 
some consensus for those recommendations. In many 
cases this may be because authors are on more than one 
of the expert committees for these guidelines, and many 
of them build on the same principles and cite the same 
sources of inspiration (ie, doing for the field what the 
Consolidated Standards of Reporting Trials did for clin-
ical trials).66 67 There are also reasons why the consensus 
was not universal—many of the publications focus on 
single aspects (eg, statistics21 or sex differences60 or 
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Recommendation
Absolute
frequency
Relative
frequency 
(%)
Management of conflicts of interest 11 18
Treatment response along 
mechanistic pathway
11 18
Interstudy standardisation of 
experimental design
10 17
Assessment of multiple 
manifestations of disease phenotype
9 15
Use of multiple time points measuring 
outcomes
9 15
Definition of treatment 8 13
Interstudy standardisation of end 
point choice
8 13
Pharmacokinetics to support 
treatment decisions
8 13
Randomised distribution of animals in 
the animal facilities
8 13
Use of validated assay for molecular 
pathways assessment
8 13
Faithful delivery of intended treatment 7 12
Addressing treatment interactions 
with clinically relevant comorbidities
6 10
Any additional elements that do not fit 
in the list above
6 10
Comparability of control group 
characteristics to those of previous 
studies
6 10
Critical appraisal of literature or 
systematic review during design 
phrase
6 10
Define programmatic purpose of 
research
6 10
Replication at different ages 6 10
Replication using variations in 
treatment
5 8
Optimisation of complex treatment 
parameters
4 7
Replication at different levels of 
disease severity
4 7
Research within multicentre consortia 4 7
Preregistration of study protocol and 
analysis procedures
3 5
Table 1 Continued
specific medical fields or diseases).13 37 38 63 In addition, 
the narrative review character of many of the publica-
tions may have led to authors focusing on elements they 
considered more important than others.
Indeed, more than half (32 out of 60) of the publi-
cations reviewed here were topical reviews by a small 
group of authors (usually fewer than five). Another 
22 (37%) were proceedings of consensus meetings or 
consensus papers set in motion by professional scientific 
or governmental organisations. It is noteworthy that none 
of these publications provide any rationale or justification 
for the validity of their recommendations. None used a 
Delphi process or other means of structured decision- 
making as suggested for clinical guidelines68 to reduce 
bias,69 and none reported using a systematic review of 
existing guidelines to inform themselves about litera-
ture. Of course, many of these expert groups will have 
been informed by pre- existing reviews (the remaining 
six included here were systematic literature reviews). 
However, there is a consistent feature across recommen-
dations—that the steps recommended to increase validity 
are considered to be self- evident, and a basis in experi-
ments and evidence is seldom linked or provided. There 
are hints that applying these principles does contribute to 
internal validity, as it has been shown that the reporting of 
measures to reduce risks of bias is associated with smaller 
outcome effect sizes,70 while other studies have not found 
such.71 However, it is unclear if these measures taken 
are the perfect ones to reduce bias, or if they are merely 
surrogate markers for more awareness and thus more 
thorough research conduct. We consider this to be prob-
lematic for at least two reasons: first, to increase compli-
ance with guidelines it is crucial to keep them as simple 
and as easy to implement as possible. An endless checklist 
can easily lead to fatalistic thinking in researchers desper-
ately wanting to publish, and it could be debated whether 
guidelines are seen by some researchers as hindering their 
progression rather than being an aide to conducting the 
best possible science, still, there is a difference between 
an ‘endless’ list and a ‘minimal set of rules’ that guaran-
tees good research reproducibility. Second, each proce-
dure that is added to experimental set- up can in itself 
lead to sources of variation, so these should be minimised 
unless it can be shown that they add value to experiments.
Compliance is a significant problem for guidelines, 
as recently reported with the widely adopted Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) 
guidelines of the UK’s National Centre for the 3Rs.66 72 
This is not attributed to blind spots in the ARRIVE guide-
lines. While enforcement by endorsing journals may be 
important,73 74 a recent randomised blinded controlled 
study suggests that even an insistence of completing an 
ARRIVE checklist has little or no impact on reporting 
quality.75 We believe that training and availability of tools 
to improve research quality will facilitate implementation 
of guidelines over time, as they become more prominent 
in researchers’ mindset.
This systematic review has important limitations. The 
main limitation is that we used single extraction only, which 
was due to feasibility, but creates a source of uncertainty 
that we cannot rule out. We decided so as we think the bias 
created here is significantly lower than in a quantitative 
extraction that includes meta- analysis. Protocol- wise, we 
only included publications in English language, reflecting 
the limited language pool of our team. Our broad search 
strategy identified more than 13 000 results, but we did not 
identify reports or systematic reviews of primary research 
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showing the importance of specific recommendations,76 
which must reflect a weakness in our search strategy. Addi-
tionally, our plan to search the websites of professional 
organisations and funding bodies failed due to reasons of 
practicality. Limiting the results included from a Google 
search would have been a practical solution to overcome 
this issue, which we failed to decide at protocol generation. 
Although being aware of single recommendations outside 
of publication, we did not include those to keep methods 
reproducible. In addition, we focused the search on ‘guide-
lines’, instead of a broader focus on adding, for example, 
‘guidance’, ‘standard’ or ‘policy’, as we feared these terms 
would inflate the search results by magnitude (particularly 
‘standard’ is a broadly used word). Hence, we cannot ascer-
tain whether we have included all important sources of 
literature. As hinted above, the results presented here also 
only paint an overview of the literature consensus, which 
should by no means be mistaken for an absolute ground 
truth of which steps need to be taken to improve internal 
validity in animal experiments. Indeed, literature debating 
the quality of these measures is sparse, and many of them 
have been borrowed from the clinical trials community or 
been considered self- evident from the literature. There is 
an urgent need for experimental testing of the importance 
of most of these measures, to provide better evidence of 
their effect.
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